牛牛AI助理已提取核心訊息
Vertex Pharmaceuticals Incorporated announced its definitive agreement to acquire Alpine Immune Sciences for $65 per share in cash, valuing the transaction at approximately $4.9 billion. The acquisition is set to enhance Vertex's portfolio with Alpine's lead asset, povetacicept, a Phase III-ready molecule for IgA nephropathy (IgAN), and other potential therapies. Povetacicept is also being evaluated for other serious immune renal diseases and cytopenias. The transaction, expected to close this quarter, will be funded through cash on hand. Vertex aims to leverage its clinical, regulatory, and commercial capabilities to expedite the development and commercialization of povetacicept, targeting approval in IgAN by 2027. The acquisition aligns with Vertex's strategy of focusing on transformative therapies for serious diseases and adds protein engineering and immunotherapy expertise to its capabilities. The tender offer for Alpine's outstanding shares has not yet commenced, and the related Tender Offer Materials and Solicitation/Recommendation Statement will be filed with the SEC and made available to Alpine's stockholders.
Vertex Pharmaceuticals Incorporated announced its definitive agreement to acquire Alpine Immune Sciences for $65 per share in cash, valuing the transaction at approximately $4.9 billion. The acquisition is set to enhance Vertex's portfolio with Alpine's lead asset, povetacicept, a Phase III-ready molecule for IgA nephropathy (IgAN), and other potential therapies. Povetacicept is also being evaluated for other serious immune renal diseases and cytopenias. The transaction, expected to close this quarter, will be funded through cash on hand. Vertex aims to leverage its clinical, regulatory, and commercial capabilities to expedite the development and commercialization of povetacicept, targeting approval in IgAN by 2027. The acquisition aligns with Vertex's strategy of focusing on transformative therapies for serious diseases and adds protein engineering and immunotherapy expertise to its capabilities. The tender offer for Alpine's outstanding shares has not yet commenced, and the related Tender Offer Materials and Solicitation/Recommendation Statement will be filed with the SEC and made available to Alpine's stockholders.
Vertex Pharmicals Incorporated宣佈了以每股65美元現金收購Alpine Immune Sciences的最終協議，交易估值約爲49億美元。此次收購將通過Alpine的主要資產povetacicept（一種用於IgA腎病（IGaN）的III期準備分子以及其他潛在療法來增強Vertex的產品組合。Povetacicept還正在評估其他嚴重的免疫性腎臟疾病和血細胞減少症。該交易預計將於本季度完成，資金將來自手頭現金。Vertex的目標是利用其臨床、監管和商業能力來加快povetacept的開發和商業化，目標是到2027年在iGaN獲得批准。此次收購符合Vertex專注於嚴重疾病變革性療法的戰略，併爲其能力增加了蛋白質工程和免疫療法的專業知識。阿爾派已發行股票的要約尚未開始，相關的要約材料和招標/建議聲明將提交給美國證券交易委員會，並提供給阿爾派的股東。
Vertex Pharmicals Incorporated宣佈了以每股65美元現金收購Alpine Immune Sciences的最終協議，交易估值約爲49億美元。此次收購將通過Alpine的主要資產povetacicept（一種用於IgA腎病（IGaN）的III期準備分子以及其他潛在療法來增強Vertex的產品組合。Povetacicept還正在評估其他嚴重的免疫性腎臟疾病和血細胞減少症。該交易預計將於本季度完成，資金將來自手頭現金。Vertex的目標是利用其臨床、監管和商業能力來加快povetacept的開發和商業化，目標是到2027年在iGaN獲得批准。此次收購符合Vertex專注於嚴重疾病變革性療法的戰略，併爲其能力增加了蛋白質工程和免疫療法的專業知識。阿爾派已發行股票的要約尚未開始，相關的要約材料和招標/建議聲明將提交給美國證券交易委員會，並提供給阿爾派的股東。
有用
沒用